AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Protalix Amends Market Offering Agreement with H.C. Wainwright for Equity Program
ByAinvest
Friday, Aug 22, 2025 8:33 pm ET1min read
Protalix BioTherapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to offer and sell shares of its common stock through an equity offering program. This aligns with the company's new registration statement and may impact its market operations and stakeholder interests. Analysts have a Hold rating with a $1.50 price target.
Protalix BioTherapeutics, Inc. (AMEX:PLX) has recently amended its At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to offer and sell shares of its common stock through an equity offering program. This move aligns with Protalix's new registration statement and could significantly impact its market operations and stakeholder interests [2].The company's stock has received a Hold rating from analysts, with a $1.50 price target. Spark, TipRanks' AI Analyst, rates Protalix as Neutral, acknowledging the company's improving financial performance and positive earnings outlook, but also noting concerns about leverage, inconsistent revenue growth, and valuation metrics [2].
Protalix's financial efficiency has been highlighted in recent reports, with a Return on Invested Capital (ROIC) of 11.43% and a Weighted Average Cost of Capital (WACC) of 5.31%, resulting in a ROIC to WACC ratio of 2.15. This indicates that Protalix generates returns more than twice its cost of capital, showcasing its financial efficiency [1].
In contrast, peers like BioLineRx Ltd., Pulmatrix, Inc., Can-Fite BioPharma Ltd., and Ardelyx, Inc. display negative ROIC to WACC ratios, highlighting the challenges faced by biopharmaceutical companies due to high research and development costs and uncertain revenue streams [1].
Protalix's ability to maintain a positive ROIC to WACC ratio sets it apart from its peers, suggesting effective capital utilization and potential attractiveness as an investment within the biopharmaceutical sector [1].
References:
[1] https://site.financialmodelingprep.com/market-news/protalix-biotherapeutics-financial-efficiency-analysis
[2] https://www.tipranks.com/news/company-announcements/protalix-amends-market-offering-agreement-with-h-c-wainwright
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet